FDA flip-flops on Alkermes' drug application

05:12 EDT 17 Apr 2018 | Pharmafile

Two weeks ago, it looked like the hopes for Alkermes’ ALKS 5461 receiving approval would rely on returning to the clinic to undergo the lengthy process of gathering more data on the drug, after it received a Refuse to File letter from the FDA.

Now, the agency has switched up its position, catching everyone off guard with its decision to accept for review Alkermes’ NDA for ALKS 5461.

As the FDA is not compelled to provide a reason for this about-face, the only information coming out of the decision is from Alkermes.

read more

Original Article: FDA flip-flops on Alkermes' drug application


More From BioPortfolio on "FDA flip-flops on Alkermes' drug application"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...